3-[6-[[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methyl-2-pyridinyl]benzoic acid
Lumacaftor
CAS: 936727-05-8
Molecular Formula: C24H18F2N2O5
3-[6-[[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methyl-2-pyridinyl]benzoic acid - Names and Identifiers
3-[6-[[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methyl-2-pyridinyl]benzoic acid - Physico-chemical Properties
| Molecular Formula | C24H18F2N2O5 |
| Molar Mass | 452.41 |
| Density | 1.51 |
| Melting Point | 200-205oC |
| Boling Point | 653.0±55.0 °C(Predicted) |
| Solubility | DMSO (Slightly), Methanol (Slightly) |
| Appearance | Solid |
| Color | White to Off-White |
| pKa | 3.95±0.10(Predicted) |
| Storage Condition | -20°C Freezer |
| Use | VX-809 (Lumacaftor) corrects CFTR mutations commonly found in cystic fibrosis by promoting the maturation of mutant CFTR(F508del-CFTR), with an EC50 of 0.1 μM. |
| In vitro study | The act of VX-809 acting at the level of the estrogen receptor (ER) causes a part of the F508del-CFTR to take a correctly folded way, exit the ER, transfer to the cell surface, and function normally. VX-809 acting on F508del-CFTR-expressing Fischer Rat Thyroid (FRT) cells VX-809 significantly increase F508del-CFTR mutation by 7.1 times with an EC50 of 0.1 μm and enhance F508del-CFTR-regulated chloride transport, the EC50 is 0.5 μm when it is increased by 5 times, while the EC50 is 7.9 μm and 16 μm when it is VRT-768. VX-809 (3 μm) acts on F508del-CFTR-expressing HEK-293 cells and increases F508del-CFTR in ER by a factor of 6. VX-809 increased CFTR maturation and chloride secretion in primary human bronchial epithelial (HBE) cells carrying F508del-CFTR mutations, with EC50 values of 350 nM and 81 nM, respectively, more effective than Corr-4a and VRT-325. VX-809 modified F508del-CFTR has a single channel development probability of 0.39, which is similar to the normal CFTR, which is 0.40. Unlike VX-770, VX-809 are not CFTR enhancers, and sharp addition of VX-809 does not affect F508del-CFTR function. In contrast to VRT-325 and Corr-4a, VX-809 does not promote the progression of normal or mutant forms of hERG or P-gp, and other disease-causing mislocalized proteins, including the α1-antitrypsin Z mutation (E342K-α1-AT) or N370S-β-glucosidase, indicating that VX-809 acts specifically on CFTR. |
3-[6-[[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methyl-2-pyridinyl]benzoic acid - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.21 ml | 11.052 ml | 22.104 ml |
| 5 mM | 0.442 ml | 2.21 ml | 4.421 ml |
| 10 mM | 0.221 ml | 1.105 ml | 2.21 ml |
| 5 mM | 0.044 ml | 0.221 ml | 0.442 ml |
Last Update：2024-01-02 23:10:35
![3-[6-[[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methyl-2-pyridinyl]benzoic acid](http://res.chembk.com/assets/str/2d/9/93/936727-05-8.png)
Supplier List
Spot supply
Product Name: VX-809 (Lumacaftor) Visit Supplier Webpage Request for quotationCAS: 936727-05-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: VX-809 (Lumacaftor) Visit Supplier Webpage Request for quotationCAS: 936727-05-8
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History
3-[6-[[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methyl-2-pyridinyl]benzoic acid
14470-28-1
14470-28-1